Synonyms 8p11 Myeloproliferative Syndrome, 8p11 Stem Cell Leukemia/Lymphoma Syndrome, 8p11 Stem Cell Lymphoma/Leukemia Syndrome + [14] |
Introduction Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype. |
Target |
Mechanism FGFR1 antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date17 Apr 2020 |
Start Date01 Sep 2022 |
Sponsor / Collaborator |
Start Date28 Mar 2017 |
Sponsor / Collaborator |
Start Date27 Feb 2017 |
Sponsor / Collaborator |